comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 22:27:28 - browse：2499

Richard Neal(D-MA), Rep. Frank Pallone (D-NJ),Rep. John Yarmuth (D-KY), Rep. Bobby Scott (D-VA) and House Minority Leader Nancy Pelosi (D-CA) attend the weekly press conference in the Capitol building on July 20, 2017 in Washington, DC. They spoke to the media about the efforts to reform the health care bill. -- health policy coverage from STAT — Reps. Richard Neal (D-Mass.), Rep. Frank Pallone (D-N.J.), and Rep. John Yarmuth (D-Ky.) Joe Raedle/Getty Images

WASHINGTON — It’s drug pricing déjà vu: Just as they did in 2019, House Democrats are pushing a bill that would allow Medicare to negotiate dozens of drug prices a year, offer those prices to all insurers, and crack down on price hikes.

Unlike then, Democrats have a starting place: the new bill represents an expansion of the major drug pricing legislation the party passed last year. But the first round of drug price negotiations hasn’t even started yet, and the law is under attack from the pharmaceutical industry in court.

The Democratic leaders of three key House committees put forth the proposal Wednesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How one patient went off dialysis — and others can too

focus

WSS

Criminal prosecution for violating HIPAA: an emerging threat

Intercept Pharmaceuticals sells itself for less than $1 billion

Addiction experts warn against a second 'war on drugs'

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Biogen shutters digital health group, ends Apple study, in cost cutting move

explore

comprehensive

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

The cancer drug shortage isn’t new — and neither are the solutions

Senator probes 340B programs at Cleveland Clinic, Bon Secours

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA advisers vote against ALS treatment from BrainStorm

New air purifier tech could be key to improving indoor air quality

Helping hospitals and community health centers plan for resilience

Psychedelics group wrestles with new pharma identity

Helping hospitals and community health centers plan for resilience

focus

It's time to retire 'poor historian' from clinicians' vocabularies

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Shingles, which affected Dianne Feinstein, is on the rise

Menendez indictment could see pharma lose a key ally

Mindstrong's demise and the future of mental health care

Mindstrong's demise and the future of mental health care

hotspot

knowledge

focus

focus